The biotech industry saw solid growth last year driven by the demand for therapies to combat COVID-19. But advances in technology helped biotech companies deliver impressive drug candidates for treating other serious ailments too. Consequently, Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (NASDAQ:BDSI) and Champions Oncology (NASDAQ:CSBR) gaining more than 45% in the near term. So, let’s evaluate these companies more closely.With more than 50% of the U.S. population now fully vaccinated for COVID-19 (according to the CDC), biotech companies have shifted their focus to research and development projects for other critical ailments. As a result, the global biotechnology market is expected to grow at a 15.8% CAGR over the next seven years to hit a $2.44 trillion market size by 2028.
Promising clinical trials have fostered increased investor optimism about the industry, as evidenced by the Invesco Dynamic Biotech & Genome ETF’s (PBE) 25.7% returns compared S&P SPDR 500 Trust Fund ETF’s (SPY) 20.4% gains over the past nine months.
Thus, Wall Street analysts believe Organogenesis Holdings Inc. (NASDAQ:ORGO), BioDelivery Sciences International, Inc. (BDSI) and Champions Oncology, Inc. (CSBR) have the potential to rally by more than 45% over the next 12 months.